Obesity and Adipose Tissue Biology
joint with Functional Neurocircuitry of Feeding and Feeding Disorders
Organizer(s): Matthias Blüher, Philipp E. Scherer and Anne BouloumiéDate: February 10 - 14, 2019
Location: Fairmont Banff Springs, Banff, AB, Canada
Obesity is a growing worldwide epidemic, increasing co-morbid conditions, such as diabetes. The joint conferences on “Obesity and Adipose Tissue Biology” and “Functional Neurocircuitry of Feeding and Feeding Disorders” are aimed to foster cross-talk between these research areas. Adipose tissue is an endocrine organ that is both controlled by and sends signals to the brain and other organs. In addition, obesity causes an inflammatory state in the adipose tissue. The recognition that brown/beige adipose tissue is active in adult humans has triggered interest in understanding the physiology and relative importance of these tissues. Exercise and bariatric surgery are known to elicit profound metabolic benefits in type 2 diabetes, although the underlying mechanisms remain unclear. This conference will bring together cell biologists, biochemists, geneticists, physiologists, drug developers and clinical researchers, thereby facilitating knowledge exchange and interactions leading to elucidation of better treatments for obesity and diabetes. Specifically, it will examine recent advances in our understanding of brown/beige adipose tissue function; obesity-induced adipose inflammation; control of adipose tissue, appetite and energy metabolism; endocrine and paracrine signaling via secreted factors; molecular mechanisms of metabolic signaling; emerging topics, including long noncoding RNA and the gut microbiome; and approaches to drug development and the treatment of obesity and diabetes.
Scholarship Deadline: October 23 2018
Discounted Abstract Deadline: October 23 2018
Abstract Deadline: November 8 2018
Discounted Registration Deadline: December 11 2018
We gratefully acknowledge additional support from these exhibitors at this conference:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Eli Lilly and Company
Novo Nordisk A/S
We gratefully acknowledge the generous grant for this conference provided by:National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Grant No. 5R13DK104611-05
Funding for this conference was made possible (in part) by 5R13DK104611-05 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.